Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

<p>Abstract</p> <p>Background</p> <p>In patients with chronic hepatitis C virus (HCV) genotype 2 or 3, 24 weeks' treatment with pegylated interferon alfa (PEG-IFN-alpha) and ribavirin induces a sustained virological response (SVR) in almost 80% of cases. Evidence s...

Full description

Bibliographic Details
Main Authors: Picardi Antonio, Arcuri Pasquale, Nosotti Lorenzo, Bonaventura Maria, Mazzoni Ettore, Barlattani Angelo, Romano Mario, Barbaro Giuseppe, Pellicelli Adriano M, Mecenate Fabrizio, Barbarini Giorgio, D'Ambrosio Cecilia, Paffetti Amerigo, Andreoli Arnaldo, Soccorsi Fabrizio
Format: Article
Language:English
Published: BMC 2010-02-01
Series:BMC Gastroenterology
Online Access:http://www.biomedcentral.com/1471-230X/10/21

Internet

http://www.biomedcentral.com/1471-230X/10/21

Similar Items